Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announces that it has acquired all device technology assets from the proprietary portfolio of SipNose Nasal Delivery Systems, a company focused on intranasal delivery platforms for local, systemic and central nervous system indications. SipNose offers a variety of devices that are designed and adapted to fit a wide range of therapies and offer the opportunity to precisely target areas of the nasal cavity to enable enhanced systemic, local or even direct-to-brain delivery.
Read the full article: Aptar Pharma Acquires Device Technology Assets of SipNose to Further Expand Intranasal Drug Delivery Portfolio //
Source: https://www.businesswire.com/news/home/20241009087185/en/Aptar-Pharma-Acquires-Device-Technology-Assets-of-SipNose-to-Further-Expand-Intranasal-Drug-Delivery-Portfolio